52 Week Range
As of on the Bolsa de Valores do Estado de Sao Paulo ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Brazil drugmaker Hypera's CEO says it will reduce discounts on drugs by year-end
Brazil's Hypera forecasts 2020 net profit of 1.3 bln reais -filing
Takeda Agrees To Divest Select OTC And Non-Core Assets In Latin America To Hypera Pharma For $825 Mln
Hypera SA, formerly Hypermarcas SA, is a Brazil-based company engaged in the pharmaceuticals sector. The Company’s major business units include Branded Prescription, Consumer Health and Branded Generics. Branded Prescription is present in the main therapeutic classes in Brazil and it operates in the Primary Care segment under the umbrella brand Mantecorp Farmasa. The Branded Prescription unit also acts as Mantecorp Skincare in dermocosmetics, with products recommended by dermatologists. Consumer Health offers non-prescription drugs, with brands such as Apracur, Benegrip, Coristina d, Engov, Epocler and Estomazil, among others. The Consumer Health unit also operates in nutritionals and vitamin supplements, with brands such as Tamarine, Vitasay, Biotonico Fontoura and Zero-Cal. Branded Generics operates under the Neo Quimica brand.
Biotechnology & Drugs
R Nova Cidade. 404, Vila Olimpia
Alvado Stainfeld Link
Chairman of the Board
Breno Toledo Pires de Oliveira
Chief Executive Officer, Member of the Board of Directors
Adalmario Ghovatto Satheler do Couto
Chief Financial Officer, Investor Relations Officer, Business Development Officer
Vivian Karina Trujillo Angiolucci
Chief Operating Officer, Member of the Executive Board
Luiz Eduardo Sales Clavis
Commercial and Marketing Vice President
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Brazilian drugmaker Hypera Pharma said its co-controlling shareholder will reimburse the company after an internal probe found "irregular payments" made by former executives in connection with a criminal investigation, sending shares more than 8% higher.
Brazilian drugmaker Hypera Pharma on Tuesday said an internal investigation found the company had made at least 110.5 million reais ($20.3 million) in "irregular payments" related to a federal criminal probe, according to a securities filing.
Brazilian pharmaceutical company Hypera SA said on Wednesday it has signed a deal with Eurofarma Laboratorios SA for the sale of a portfolio of 12 products in Argentina, Colombia, Ecuador, Mexico, Panama and Peru for $161 million.
* BRAZIL'S HYPERA SEES 2020 NET REVENUE OF 4.25 BILLION REAIS TO 4.35 BILLION REAIS -FILING
Brazilian pharmaceutical company Hypera SA <HYPE3.SA> said on Wednesday it has agreed to buy Boehringer Ingelheim's Buscopan brand and other assets for 1.3 bln reais ($319 million).
Brazilian pharmaceutical company EMS is expected to offer 1.5 billion reais ($357.5 million) to acquire painkiller brand Buscopan from German company Boehringer Ingelheim and its Brazilian rival Hypera SA is also interested in the deal, one source with knowledge of the matter...
The controlling shareholder of Brazil's Hypera SA is in initial talks about a plea deal, Brazil's Valor Economico newspaper reported on Wednesday, as the pharmaceutical company continues an internal probe into alleged corruption.
Quarterly profit at Hypera SA , Brazil's largest listed producer of over-the-counter medicine, rose 22.3 percent on a yearly basis in the second quarter as revenues increased more than 10 percent due to higher overall sales.
Brazilian pharmaceuticals company Hypera SA said on Wednesday that its board had appointed an independent committee to investigate alleged corruption by former executives.
Brazilian pharmaceutical company Hypera SA is in talks to agree to a leniency deal with prosecutors that could include a 2 billion reais ($540 million) fine, newspaper Valor Economico reported on Thursday, an agreement that Hypera denied.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.